Course Library

Printable Courses PDF

Search by Keyword

Learning at Dana-Farber Online Courses

  • Use of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia

    Course Experts: Sandra Savaya, PharmD

    Course Description: This course reviews the background information and pathophysiology of chronic lymphocytic leukemia (CLL), compares Bruton tyrosine kinase (BTK) inhibitors for CLL, and outlines the future of CLL treatment using new therapies.

    Credits: CEUs will be granted to pharmacists in disease state management/drug therapy.

    Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis

  • Updates to VTE in Oncology: A Clinical Opportunity for Advanced Practice Pharmacy

    Course Experts: Beata Rucinski, PharmD and Jean Connors, MD

    Course Description: This course describes the place in therapy of direct oral anticoagulants (DOACs) in cancer associated VTEs and reviews the evidence that influences cancer associated anticoagulation guidelines.

    Credits: CEUs will be granted for pharmacists in disease state management/drug therapy.

    Venous Thromboembolism (VTE), Anticoagulation, Direct Oral Anticoagulants (DOACs), Collaborative Drug Therapy Management (CDTM), Anticoagulation Management Service (AMS), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), National Comprehensive Cancer Network (NCCN), Warfarin, Low Molecular Weight Heparin (LMWH), Apixaban, Edoxaban, Rivaroxaban, Dalteparin, Enoxapari...

  • Updates in Metastatic Breast Cancer

    Course Experts: Niti Patel, PharmD

    Course Description: This course reviews new agents and new indications for treatment of metastatic breast cancer, as well as how to navigate the new algorithm of treating metastatic breast cancer based on recently published literature.

    Credits: CEUs will be granted to pharmacists in disease state management/drug therapy.

    Metastatic, Breast Cancer, HER2, Hormone Receptor (HR), Triple Negative Breast Cancer (TNBC), Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), De Novo, Lymph Nodes, Trastuzumab Deruxtecan (T-DXd), Sacituzumab Govitecan, CDK 4/6 Inhibitors, Ribociclib, Elacestrant, Selective Estrogen Receptor Degrader (SERD), ESR1 Mutation, Aromatase Inhibitor (AI), Pr...

  • Sterile Compounding of Hazardous Drugs: An Overview of USP <800>

    Course Experts: Angela Chen, PharmD, BCPS

    Course Description: This course reviews USP <800> and recommended best practices for developing a comprehensive and compliant hazardous drug program.

    Credits: CEUs will be granted for pharmacists and pharmacy technicians in compounding.

    USP 800, Hazardous Drugs (HDs), Sterile Compounding, Personnel Training, Engineering Controls, C-PEC (Containment Primary Engineering Control), C-SEC (Containment Secondary Engineering Control), C-SCA (Containment Sterile Compounding Area), PPE (Personal Protective Equipment), Closed System Transfer Devices (CSTDs), Deactivation, Decontamination, Cleaning, Disinfection, Environmental Quality, NIOSH (National Institute for Occupational Safety a...

  • Regulations Associated with Requests for Hastened Death

    Course Experts: Allyson Beechy, PharmD

    Course Description: This course defines the terminology associated with hastened death, the ethical conversations surrounding it, and the legal requirements for hastened death in states with active legislation.

    Credits: CEUs will be granted for pharmacists in law related to pharmacy practice.

    Hastened Death, Medical Aid in Dying, Assisted Suicide, Euthanasia, Terminal Illness, Ethical Considerations, Legislation, Death with Dignity, Autonomy, Palliative Care, Prognosis, Oral Request, Written Request, Attending Physician, Consulting Physician, Mental Health Assessment, Self-Administration, Barbiturates, Controlled Substances, Life Insurance

  • Provision of Safe Access to Opioids in Patients with Advanced Cancer in the Setting of Opioid Epidemic

    Course Experts: Joey Ricciutti, PharmD and Ben Kematick, PharmD, BCACP

    Course Description: This course reviews the key events in the opioid epidemic and how those events impacted the perception of opioid use. For patients with advanced cancer, barriers, risks, and benefits of opioid use are discussed, as well as methods for assessing, monitoring, and treating their pain.

    Credits: CEUs will be granted for pharmacists in pain management.

    Opioid Epidemic, Advanced Cancer, Pain Management, Opioid Access, Opioid Utilization, Opioid Risks, Opioid Benefits, Pain Assessment, Pain Monitoring, Opioid Misuse, Opioid Toxicity, Non-Opioid Analgesics, Interventional Pain Management, Opioid Sparing, Risk Mitigation, Total Pain, Opioid Ris...

  • Oncology Pharmacogenomics and the Evolving Landscape of Targeted Therapies

    Course Experts: Jennifer Espiritu, PharmD, BCOP, CCRP

    Course Description: This course reviews basic genomic principles relevant to oncology, interprets patient-specific genomic profiles, and discusses significance of select mutations and their potential as therapeutic targets.

    Credits: CEUs will be granted for pharmacists in disease state management/drug therapy.

    Pharmacogenomics, Germline Mutations, Somatic Mutations, BRCA, Oncogenic Mutations, Gain of Function, Loss of Function, DNA Transcription, RNA Translation, Codons, Point Mutations, Missense Mutations, Silent Mutations, Nonsense Mutations, Frameshift Mutations, Amplification, HER2, Chromosomal Rearrangement, Microsatellite Instability, Tumor Mutational Burden (TMB)<...

  • Multiple Myeloma: Miracles or Misfits

    Course Experts: Houry Leblebjian, PharmD, BCOP and Omar Marzouk, PharmD

    Course Description: This course describes recent recommendations for newly diagnosed myeloma and evaluates the role of approved treatment options in relapsed/refractory multiple myeloma.

    Credits: CEUs will be granted for pharmacists in disease state management.

    Myeloma, CRAB Criteria, Hypercalcemia, Extramedullary Plasmacytomas, Hyperviscosity, Hypogammaglobulinemia, Amyloidosis, NCCN (National Comprehensive Cancer Network), Autologous Stem Cell Transplant, Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, GRIFFIN Study, LYRA Trial, Panobinostat, Selinexor, Belantamab Mafodotin, CAR-T Therapy

  • Medication Safety Part 2: Roles & Responsibilities of the Medication Safety Officer

    Course Experts: Emily Messing, PharmD, BCPS and Andrew Stivers, PharmD

    Course Description: This course reviews the roles and responsibilities of the medication safety officer and summarizes activities led by the medication safety officer to improve safety within an organization.

    Credits: CEUs will be granted to pharmacists and pharmacy technicians in patient safety.

  • Medication Safety Part 1: The Medication Use System in the Ambulatory Oncology Setting

    Course Experts: Emily Messing, PharmD, BCPS and Andrew Stivers, PharmD

    Course Description: This course reviews the phases of the medication use system and their relevance to oncology care and the risk reduction strategies in place at Dana-Farber Cancer Institute that enhance safe medication use.

    Credits: CEUs will be granted to pharmacists and pharmacy technicians in patient safety.

  • Measuring What Matters: Safety Culture Surveys

    Course Experts: Merihan Raouf, PharmD

    Course Description: This course reviews patient safety culture, the importance of measuring safety culture through safety culture surveys, and converting the survey results into actionable items.

    Credits: CEUs will be granted to pharmacists, pharmacy technicians and nurses in patient safety.

    Safety Culture, Surveys, Organizational Culture, Patient Safety, Teamwork, Communication, Just Culture, Reporting, AHRQ, Likert Scale, SAQ (Safety Attitudes Questionnaire), SOPS (Surveys on Patient Safety Culture), Debriefing, Action Planning, Clinical Outcomes, SSER (Serious Safety Event Rate), PHI (Preventable Harm Index), ICU (Intensive Care Unit), CLABSI (Central Line-Associated Bloodstream Inf...

  • Lung Cancer Pharmacotherapy

    Course Experts: Maria Vecchiarelli Kimball, PharmD, BCOP

    Course Description: This course provides an overview of chemotherapy, immunotherapy, and targeted therapy families of drugs that are commonly used in the treatment of small cell and non-small cell lung cancer. It identifies common treatment regimens, adverse effects, and unique toxicities pertinent to each agent or combination regimen.

    Credits: CEUs will be granted for pharmacists in disease state management/drug therapy.

    Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Chemotherapy, Biotherapy, Targeted Therapy, Adverse Effects, Taxanes, Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Vinca Alkaloids, Immune Checkpoint Inh...